• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Etoposid “Ebewe”
    / Novartis


    Active Ingredient
    Etoposide 20 mg/ml

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Vial

    1 x 100 mg / 5 ml

    partial basket chart 61048 5185

    Vial

    1 x 200 mg / 10 ml

    partial basket chart 61049 5418

    Vial

    1 x 1000 mg / 50 ml

    partial basket chart 15925 5450

    Related information


    Dosage

    Etoposid “EBEWE” is only administered by slow infusion over 30 minutes to 2 hours.
    Etoposide concentrate for solution for infusion must be diluted before use.
    Adults: The recommended dose of Etoposid “EBEWE” is 60-120 mg/m² i.v. per day for 5 subsequent days. As Etoposid “EBEWE” causes myelosuppression, the course of treatment must not be repeated more often than with intervals of 21 days. Repeated courses of treatment with Etoposid “EBEWE” infusion must not be given before the blood picture has been controlled for signs of myelosuppression and found satisfactory.
    Paediatric patients: Safety and efficacy in children have not been established.
    Elderly: Dose adjustment is not necessary.
    Renal impairment: In patients with renal impairment but with normal hepatic function, the dose of etoposide must be reduced and haematological minimum values and renal function must be monitored.
    See prescribing information for full details.


    Indications

    Etoposide may be administered alone or in combination with other cytostatic drugs in the treatment of small cell lung cancer or resistant non-seminomatous testicular carcinoma.
    Etoposide, when given in combination with other chemotherapeutic agents, has been shown to be of benefit in treating the following malignancies: Hodgkin’s and non-Hodgkin’s lymphoma, acute myelocytic leukemia.


    Contra-Indications

    • patients who have shown hypersensitivity to podophyllotoxin derivatives or to any of the excipients.
    • patients with severe hepatic impairment.
    • patients with severe renal impairment (creatinine clearance <15 ml/min).
    • patients with severe myelosuppression.


    Manufacturer
    Ebewe Pharma
    Licence holder
    CLOSE